181 filings
ARS
2023 FY
EQ
Equillium Inc
11 Apr 24
Annual report to shareholders
4:09pm
DEFA14A
EQ
Equillium Inc
11 Apr 24
Additional proxy soliciting materials
4:07pm
DEF 14A
EQ
Equillium Inc
Definitive proxy
11 Apr 24
4:06pm
PRE 14A
EQ
Equillium Inc
Preliminary proxy
1 Apr 24
5:06pm
8-K
EQ
Equillium Inc
1 Apr 24
Other Events
8:05am
S-8
9qlu8j
25 Mar 24
Registration of securities for employees
4:26pm
8-K
z7q3crc8gf49art
25 Mar 24
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
4:05pm
8-K
qrn5l5cxh emgzaq26z
8 Mar 24
Departure of Directors or Certain Officers
4:01pm
8-K
r14vgb i86c
23 Feb 24
Results of Operations and Financial Condition
5:12pm
424B5
gfg b05ekj
23 Feb 24
Prospectus supplement for primary offering
5:09pm
8-K
t1os423dxbzq
22 Feb 24
Other Events
6:08am
8-K
55gy949tn
21 Dec 23
Other Events
8:05am
8-K
v8i5oh1t
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
8-K
oksco1yp4vdax0hdbdi8
16 Oct 23
Regulation FD Disclosure
8:05am
8-K
4gll39e4dcbc
5 Oct 23
Entry into a Material Definitive Agreement
5:28pm
424B5
jkgqo5
5 Oct 23
Prospectus supplement for primary offering
5:23pm
8-K
kfya4 ujsrqnbd6log
9 Aug 23
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
4:06pm